-+ 0.00%
-+ 0.00%
-+ 0.00%

Corcept Q1 turns to USD 31.8 million net loss; revenue rises to USD 164.9 million

PUBT·04/30/2026 20:21:37
Listen to the news
Corcept Q1 turns to USD 31.8 million net loss; revenue rises to USD 164.9 million
  • Corcept posted a net loss of USD 31.8 million in first quarter 2026, swinging from net income a year earlier.
  • Revenue rose 4.9% to USD 164.9 million.
  • Operating loss widened to USD 49.6 million as operating expenses climbed to USD 214.5 million, due to higher spending to prepare for Lifyorli launch and to invest in Cushing’s syndrome growth initiatives.
  • Cash and investments slipped to USD 515.4 million at March 31, 2026, while Lifyorli (relacorilant) gained FDA approval in March for platinum-resistant ovarian cancer.
  • Corcept raised 2026 revenue guidance to USD 950 million-USD 1.05 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202604301605BIZWIRE_USPR_____20260430_BW059913) on April 30, 2026, and is solely responsible for the information contained therein.